Sugi Predict

Sugi Predict / Compounds / SCHEMBL4397334

SCHEMBL4397334

SCHEMBL4397334

COc1ccc(CN2C(=O)N(Cc3ccc(OC)cc3)[C@H](c3cccc(Br)c3)C2c2cccc(Br)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ CMA1 P23946 1/20 0.47
▸ MAPT P10636 5/20 0.45
▸ THRB P10828 1/20 0.45
▸ PARK7 Q99497 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ CHRM5 P08912 1/20 0.43
▸ TP53 P04637 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ HCRTR1 O43613 1/20 0.42
▸ HCRTR2 O43614 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13811863 0.81 MEN1 (0.44) MEN1KMT2ACMA1MAPTALDH1A1
SCHEMBL4397603 0.81 MEN1 (0.44) MEN1KMT2ACMA1MAPTALDH1A1
SCHEMBL4404922 0.78 MEN1 (0.42) MEN1KMT2ACMA1MAPTALDH1A1
SCHEMBL4404919 0.76 MEN1 (0.40) MEN1KMT2ACMA1MAPTALDH1A1
SCHEMBL13821232 0.74 MEN1 (0.39) MEN1KMT2ACMA1MAPTALDH1A1
SCHEMBL30643692 0.73 ALDH1A1 (0.46) MEN1KMT2ACMA1MAPTPARK7
SCHEMBL5230693 0.73 ALDH1A1 (0.43) MEN1KMT2AALDH1A1LMNAHCRTR1
SCHEMBL4397339 0.70 P2RX4 (0.49) MEN1KMT2ACMA1MAPTTHRB
SCHEMBL5151519 0.70 KMT2A (0.74) MEN1KMT2AMAPTALDH1A1HCRTR1
SCHEMBL31435438 0.69 MEN1 (0.53) MEN1KMT2ACMA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553809-B2 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2009-06-30 — — US disclosed
US-20060057144-A1 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2006-03-16 — — US disclosed
US-6835753-B2 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED (AU) 2004-12-28 — — US disclosed
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED 2002-05-23 — — US disclosed
US-6355683-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE ILEXUS PTY LIMITED (AU) 2002-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt FCGR2A, FCGR1A, FCER2 MEN1 4070/4885KMT2A 2002/4885CMA1 434/4885
US-20060057144-A1 Fc receptor modulators and uses thereof FCGR1A, FCER2, FCGR2A MEN1 3751/4885KMT2A 3334/4885CMA1 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.